SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-152607
Filing Date
2021-12-22
Accepted
2021-12-22 16:05:42
Documents
15
Period of Report
2021-12-22
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2136140d1_8k.htm   iXBRL 8-K 26524
2 EXHIBIT 99.1 tm2136140d1_ex99-1.htm EX-99.1 53531
7 GRAPHIC tm2136140d1_ex99-1img001.jpg GRAPHIC 9675
  Complete submission text file 0001104659-21-152607.txt   325017

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA otlk-20211222.xsd EX-101.SCH 3552
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE otlk-20211222_def.xml EX-101.DEF 26932
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20211222_lab.xml EX-101.LAB 36890
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20211222_pre.xml EX-101.PRE 25550
9 EXTRACTED XBRL INSTANCE DOCUMENT tm2136140d1_8k_htm.xml XML 5308
Mailing Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830
Business Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 211513272
SIC: 2836 Biological Products, (No Diagnostic Substances)